Dr. Sumathi Nambiar is Director of the Division of Anti-Infective Products, Office of Antimicrobial Products, since July 2013. Dr. Nambiar joined the Division of Anti-Infective Products in 2002. In her current role, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs.
Dr. Nambiar is board-certified in pediatrics and pediatric infectious diseases. She completed her pediatric residency at the Inova Fairfax Hospital for Children, VA and her fellowship in pediatric infectious diseases at Children’s National Medical Center, Washington DC. She received her MPH from The George University School of Public Health.
Dr. Nambiar will be delivering a keynote speech at World Anti-Microbial Resistance Congress USA 2016 about ‘Addressing pediatric antibacterial drug development’. This keynote will feature an overview of the Pediatric Research Equality Act (PREA) to conduct trials in children, as well as discussion of the importance of these trials to achieve enhanced knowledge on dosing and effectiveness of drugs and practical and ethical challenges when studying antibacterial drugs in neonates and infants. To hear from Dr. Nambiar and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.